Short report: plasma aluminium concentration and 24-hour urinary aluminium excretion before, during and after treatment with sucralfate.
Ten dyspeptic patients were treated with 1 g sucralfate q.d.s. for six weeks. The plasma aluminium concentration and 24-h urinary aluminium excretion were measured at 3-weekly intervals before, during and after treatment with sucralfate. Compared with before treatment, there were significant rises in the median plasma aluminium concentration at 3 and 6 weeks during treatment with sucralfate (6 micrograms/L to 13 and 12 micrograms/L). The median 24-h urinary aluminium excretion rose significantly from a pretreatment level of 20 micrograms to 71 and 78 micrograms after 3 and 6 weeks of treatment; the significant increase of urinary aluminium excretion persisted for three weeks after cessation of treatment (52 micrograms/24 hours), but thereafter urinary excretion was not significantly different from pretreatment. The results are consistent with significant absorption and tissue accumulation of aluminium during standard treatment with sucralfate in individuals with normal renal function.
Mistry
P
P
University Department of Medicine, Royal Free Hospital School of Medicine, London, UK.
Varghese
Z
Z
Pounder
R E
RE
D000328:Adult; D000368:Aged; D000535:Aluminum / Q000097:blood / Q000378:metabolism* / Q000652:urine; D004415:Dyspepsia / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013392:Sucralfate / Q000493:pharmacokinetics* / Q000627:therapeutic use; D013997:Time Factors
D013392:Sucralfate; D000535:Aluminum